Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed


GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration and a generic Advair launch this year was now "highly unlikely".



from Biotech News